Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN

• Ajay K. Nooka,
• Jonathan L. Kaufman,
• Cesar Rodriguez,
• Andrzej Jakubowiak,
• Yvonne Efebera,
• Brandi Reeves,
• Tanya Wildes,
• Sarah A. Holstein,
• Larry D. Anderson,
• Ashraf Badros,
• Leyla Shune,
• Ajai Chari,
• Huiling Pei,
• Annelore Cortoos,
• Sharmila Patel,
• J. Blake Bartlett,
• Jessica Vermeulen,
• Thomas S. Lin,
• Paul G. Richardson,
• Peter Voorhees

Affiliations

Ajay K. Nooka

Winship Cancer Institute, Emory University

Jonathan L. Kaufman

Winship Cancer Institute, Emory University

Cesar Rodriguez

Wake Forest University School of Medicine

Andrzej Jakubowiak

University of Chicago Medical Center

Yvonne Efebera

OhioHealth

Brandi Reeves

University of North Carolina—Chapel Hill

Tanya Wildes

Cancer & Aging Research Group

Sarah A. Holstein

Division of Oncology & Hematology, Department of Internal Medicine, University of Nebraska Medical Center

Larry D. Anderson

Simmons Comprehensive Cancer Center, UT Southwestern Medical Center

Ashraf Badros

Greenbaum Cancer Center, University of Maryland

Leyla Shune

Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center

Ajai Chari

Tisch Cancer Institute, Mount Sinai School of Medicine

Huiling Pei

Janssen Research & Development, LLC

Annelore Cortoos

Janssen Scientific Affairs, LLC

Sharmila Patel

Janssen Scientific Affairs, LLC

J. Blake Bartlett

Janssen Research & Development, LLC

Jessica Vermeulen

Janssen Research & Development, LLC

Thomas S. Lin

Janssen Scientific Affairs, LLC

Paul G. Richardson

Dana-Farber Cancer Institute

Peter Voorhees

Levine Cancer Institute, Atrium Health